Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2018 April;70(2) > Minerva Ginecologica 2018 April;70(2):150-70

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEW  


Minerva Ginecologica 2018 April;70(2):150-70

DOI: 10.23736/S0026-4784.17.04152-1

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use

Christine WALSH

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA


PDF  


INTRODUCTION: Poly(ADP-ribose) polymerase (PARP) inhibitors are a targeted therapy option for ovarian cancer. The goal of this review was to organize and summarize the clinical trials evaluating PARP inhibitor therapy in ovarian cancer as monotherapy, maintenance therapy after partial or complete remission to therapy or as a part of a combination regimen.
EVIDENCE ACQUISITION: PubMed, ClinicalTrials.gov, data from the United States Food and Drug Administration (US FDA) and proceedings from scientific conferences were searched for published and unpublished data pertaining to clinical trials and approvals of PARP inhibitor use in ovarian cancer.
EVIDENCE SYNTHESIS: There have been 36 published phase 1, 2 and 3 studies evaluating the use of olaparib, niraparib, veliparib and rucaparib in ovarian cancer. Olaparib and rucaparib have been approved by the US FDA as monotherapy for advanced recurrent ovarian cancer. Niraparib and olaparib have been approved by the US FDA for maintenance therapy after partial or complete remission in recurrent ovarian cancer. There are currently ten phase 3 trials evaluating PARP inhibitors at various timepoints in ovarian cancer therapy including at the time of primary adjuvant therapy, as maintenance therapy after primary chemotherapy, as monotherapy for recurrent cancer and as maintenance therapy after chemotherapy for recurrence.
CONCLUSIONS: The landscape of PARP inhibitor use for ovarian cancer is rapidly evolving and PARP inhibitors have become more available as a targeted therapy option for ovarian cancer treatment.


KEY WORDS: Poly(ADP-ribose) polymerase inhibitors - Ovarian epithelial cancer - Genes, BRCA1 - Genes, BRCA2

top of page

Publication History

Issue published online: February 2, 2018
Article first published online: October 9, 2017
Manuscript accepted: October 5, 2017
Manuscript received: September 30, 2017

Cite this article as

Walsh C. Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use. Minerva Ginecol 2018;70:150-70. DOI: 10.23736/S0026-4784.17.04152-1

Corresponding author e-mail

walshc@cshs.org